The 63rd American Academy of Neurology’s 2011 Annual Meeting

Highlights from the AAN 2011 Annual Meeting include the relationship between cardiovascular risk factors and cognitive decline, using a cerebrospinal fluid test to determine MS onset of disability, an experimental agent for MS, and overcoming dyskinesia in Parkinson’s. » Amphetamine Use May Increase Parkinson’s Risk » Cardiovascular Risk Factors & Cognitive Decline » Experimental Agent Promising for MS Sufferers » Overcoming Dyskinesia in Parkinson’s » CSF Test May Help Predict MS Onset of Disability Amphetamine Use May Increase Parkinson’s Risk The Particulars: Amphetamines were once recommended for treating patients with Parkinson’s disease. Recent studies, however, have suggested that this class of drugs may be linked to a higher risk of developing Parkinson’s. Data Breakdown: Researchers conducted an analysis in 66,438 individuals who did not have Parkinson’s disease at baseline and collected information on exposure to amphetamines. Through a mean follow-up of 38.8 years, 1,154 patients received a Parkinson’s diagnosis. The average age at baseline was 36, and the average age at diagnosis was 70. Individuals who reported often taking amphetamine sulfate or dextroamphetamine sulfate had a 56% greater risk of having a Parkinson’s diagnosis decades later. The magnitude of the relationship was similar for both men and women. Participants who reported taking weight-loss medication at baseline did not have an elevated risk for Parkinson’s disease through follow-up (hazard ratio, 0.95). Take Home Pearls: The use of amphetamines appears to be associated with an elevated risk for developing Parkinson’s disease later in life. Considering the wide population exposure to both legal and illegal amphetamines, more studies are needed to address this association. Cardiovascular Risk Factors & Cognitive Decline [back to top] The Particulars: The heart...